Key result
MIMVR is linked to ~2% 30-day mortality, indicating safety even in redo and elderly patients.
Why the study?
To analyze the early and mid-term outcomes, including short-term morbidity and mortality, of minimally invasive mitral valve replacement including redo-operations and elderly patients.
Does minimally invasive mitral valve replacement provide safe and effective outcomes in patients including redo-surgery and elderly patients?
Observational (n=55)
No
Does minimally invasive mitral valve replacement provide safe and effective outcomes in patients including redo-surgery and elderly patients?
Minimally invasive mitral valve replacement is a safe and effective option with acceptable early and mid-term outcomes, even for high-risk groups like redo-surgery and elderly patients.
Supports use in redo and elderly patients; leaves open need for randomized confirmation.
Background: Minimally invasive mitral valve surgery has been established as a routine procedure at our institution. In the present study, early and mid-term outcomes of patients who underwent minimally invasive mitral valve replacement (MIMVR), including redo-operations and elderly patients, during the 5-year post-surgery period were analyzed to review short-term morbidity and mortality, and mid-term results. Methods: Preoperative variables, intraoperative findings, and postoperative outcomes of MIMVR patients treated from January 2014 to November 2020 and prospectively stored in a database were reviewed. Survival and freedom from cerebrovascular events were evaluated using life tables and Kaplan-Meier analysis. Results: A total of 445 patients underwent minimally invasive mitral valve surgery during the study period, of whom 55 received mitral valve replacement (MVR), including 18 cases of redo-MVR and 10 elderly (≥80 years old) patients. Mean age at the time of surgery was 70.7±11.3 years. The number of patients who underwent conversion to a sternotomy was 0, while 30-day mortality was noted in one (2%). For all MIMVR cases, 1- and 5-year survival was 90.8±3.9 % and 76.5±7.1%, respectively. Furthermore, freedom from cerebrovascular events and anticoagulation-related complications was 94.3±3.2% and 84.2±6.3% at 1 and 5 years, respectively. In univariate analysis, independent predictors of hospital mortality and prolonged hospital stay included infectious endocarditis, while previous cardiac surgery and elderly status were not significant factors. Conclusions: MIMVR can be performed safely and effectively for redo-MVR and in elderly patients with very few perioperative complications. Early and mid-term outcomes in the present cohort were acceptable.
No takes yet. Share an insight, caveat, or question.
Nakayama et al. (2024) conducted an observational in Mitral valve disease requiring replacement (n=55). Minimally invasive mitral valve replacement was evaluated on 30-day mortality. Minimally invasive mitral valve replacement was associated with a 2% 30-day mortality and 76.5% 5-year survival, demonstrating safety and efficacy even in redo and elderly patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: